全文获取类型
收费全文 | 180512篇 |
免费 | 11973篇 |
国内免费 | 707篇 |
专业分类
耳鼻咽喉 | 2529篇 |
儿科学 | 4928篇 |
妇产科学 | 3456篇 |
基础医学 | 23468篇 |
口腔科学 | 3560篇 |
临床医学 | 17695篇 |
内科学 | 38612篇 |
皮肤病学 | 3000篇 |
神经病学 | 18161篇 |
特种医学 | 6275篇 |
外国民族医学 | 13篇 |
外科学 | 26775篇 |
综合类 | 2324篇 |
现状与发展 | 3篇 |
一般理论 | 203篇 |
预防医学 | 13452篇 |
眼科学 | 4895篇 |
药学 | 11656篇 |
中国医学 | 206篇 |
肿瘤学 | 11981篇 |
出版年
2023年 | 701篇 |
2022年 | 1229篇 |
2021年 | 2913篇 |
2020年 | 1773篇 |
2019年 | 2921篇 |
2018年 | 3444篇 |
2017年 | 2480篇 |
2016年 | 2892篇 |
2015年 | 3495篇 |
2014年 | 5164篇 |
2013年 | 7941篇 |
2012年 | 11497篇 |
2011年 | 12360篇 |
2010年 | 6891篇 |
2009年 | 6367篇 |
2008年 | 11622篇 |
2007年 | 12394篇 |
2006年 | 11912篇 |
2005年 | 12255篇 |
2004年 | 11648篇 |
2003年 | 11100篇 |
2002年 | 10711篇 |
2001年 | 1554篇 |
2000年 | 1189篇 |
1999年 | 1646篇 |
1998年 | 2347篇 |
1997年 | 2036篇 |
1996年 | 1714篇 |
1995年 | 1594篇 |
1994年 | 1436篇 |
1993年 | 1362篇 |
1992年 | 1078篇 |
1991年 | 1003篇 |
1990年 | 872篇 |
1989年 | 852篇 |
1988年 | 869篇 |
1987年 | 745篇 |
1986年 | 861篇 |
1985年 | 940篇 |
1984年 | 1243篇 |
1983年 | 1191篇 |
1982年 | 1657篇 |
1981年 | 1521篇 |
1980年 | 1432篇 |
1979年 | 819篇 |
1978年 | 925篇 |
1977年 | 809篇 |
1976年 | 721篇 |
1975年 | 582篇 |
1974年 | 613篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
31.
Ramya C. Mosarla Muthiah Vaduganathan Arman Qamar Javid Moslehi Gregory Piazza Robert P. Giugliano 《Journal of the American College of Cardiology》2019,73(11):1336-1349
Patients with active cancer are at an increased risk of arterial and venous thromboembolism (VTE) and bleeding events. Historically, in patients with cancer, low molecular weight heparins have been preferred for treatment of VTE, whereas warfarin has been the standard anticoagulant for stroke prevention in patients with atrial fibrillation (AF). More recently, direct oral anticoagulants (DOACs) have been demonstrated to reduce the risk of venous and arterial thromboembolism in large randomized clinical trials of patients with VTE and AF, respectively, thus providing an attractive oral dosing option that does not require routine laboratory monitoring. In this review, we summarize available clinical trial data and guideline recommendations, and outline a practical approach to anticoagulation management of VTE and AF in cancer. 相似文献
32.
Stefaniuk Catherine M. Schlegelmilch June Meyerson Howard J. Harding Clifford V. Maitta Robert W. 《Journal of thrombosis and thrombolysis》2022,53(4):950-953
Journal of Thrombosis and Thrombolysis - Over the last few years data from our group have indicated that α-synuclein is important in development of immune cells as well as potentially... 相似文献
33.
34.
Stefan Scholz Florian Koerber Kinga Meszaros Rosa Maya Fassbender Bernhard Ultsch Robert R. Welte Wolfgang Greiner 《Vaccine》2019,37(12):1692-1701
Introduction
Invasive meningococcal disease (IMD) is a severe disease mainly affecting infants and young children. The most common serogroup causing IMD in Germany is the serogroup type B Neisseria meningitidis (MenB). The aim of the present study is to estimate the economic burden of MenB-related IMD in Germany.Method
A bottom-up, model-based costing approach has been used to calculate the diagnose- and age-specific yearly lifetime costs of a hypothetical cohort of MenB-related IMD cases. Direct costs contain the treatment cost for the acute phase of the disease, long-term sequelae, costs for rehabilitation, and public health response. Indirect costs are calculated for the human-capital approach and the friction-cost approach considering productivity losses of patients or parents for the acute phase and long-term sequelae. Publicly available databases from the Federal Statistical Office, the SOEP panel data set, literature, and expert opinion were used as data sources. All future costs beyond the reference year of 2015 were discounted at 3%.Results
The total costs for the hypothetical cohort (343 patients) from a societal perspective are €19.6 million (€57,100/IMD case) using the friction-cost approach and €58.8 million (€171,000/IMD case) using the human-capital approach. Direct costs amount to €18.6 million or €54,300 €/case. Sequelae are responsible for 81% of the direct costs/case.Discussion
The elevated costs/MenB-related IMD case reflect the severity of the disease. The total costs are sensitive to the productivity-loss estimation approach applied. MenB is an uncommon but severe disease; The costs/case reflect the severity of the disease and is within the same magnitude as for human papilloma virus infections. The available literature on sequelae is due to the uncommonness limited and heterogeneous. 相似文献35.
36.
37.
38.
39.
40.
Catherine L. Omosule Dominique Joseph Brooke Weiler Victoria L. Gremminger Spencer Silvey Youngjae Jeong Ashique Rafique Pamela Krueger Sandra Kleiner Charlotte L. Phillips 《Journal of bone and mineral research》2022,37(5):938-953
Osteogenesis imperfecta (OI) is a collagen-related bone disorder characterized by fragile osteopenic bone and muscle weakness. We have previously shown that the soluble activin receptor type IIB decoy (sActRIIB) molecule increases muscle mass and improves bone strength in the mild to moderate G610C mouse model of OI. The sActRIIB molecule binds multiple transforming growth factor-β (TGF-β) ligands, including myostatin and activin A. Here, we investigate the musculoskeletal effects of inhibiting activin A alone, myostatin alone, or both myostatin and activin A in wild-type (Wt) and heterozygous G610C (+/G610C) mice using specific monoclonal antibodies. Male and female Wt and +/G610C mice were treated twice weekly with intraperitoneal injections of monoclonal control antibody (Ctrl-Ab, Regn1945), anti-activin A antibody (ActA-Ab, Regn2476), anti-myostatin antibody (Mstn-Ab, Regn647), or both ActA-Ab and Mstn-Ab (Combo, Regn2476, and Regn647) from 5 to 16 weeks of age. Prior to euthanasia, whole body composition, metabolism and muscle force generation assessments were performed. Post euthanasia, hindlimb muscles were evaluated for mass, and femurs were evaluated for changes in microarchitecture and biomechanical strength using micro–computed tomography (μCT) and three-point bend analyses. ActA-Ab treatment minimally impacted the +/G610C musculoskeleton, and was detrimental to bone strength in male +/G610C mice. Mstn-Ab treatment, as previously reported, resulted in substantial increases in hindlimb muscle weights and overall body weights in Wt and male +/G610C mice, but had minimal skeletal impact in +/G610C mice. Conversely, the Combo treatment outperformed ActA-Ab alone or Mstn-Ab alone, consistently increasing hindlimb muscle and body weights regardless of sex or genotype and improving bone microarchitecture and strength in both male and female +/G610C and Wt mice. Combinatorial inhibition of activin A and myostatin more potently increased muscle mass and bone microarchitecture and strength than either antibody alone, recapturing most of the observed benefits of sActRIIB treatment in +/G610C mice. © 2022 American Society for Bone and Mineral Research (ASBMR). 相似文献